Drug intelligence / Profile preview

aceclofenac + paracetamol (Amvia Biotech)

Development stage: Unknown
Lead developer: Amvia Biotech
Modality: Small Molecules
Administration: Oral

Overview

Bitugesic AC is a fixed-dose combination analgesic and anti-inflammatory medication developed by Amvia Biotech. It contains aceclofenac (100 mg), a non-steroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase enzymes (COX-1 and COX-2), and paracetamol (325 mg), an analgesic and antipyretic agent. This combination is primarily indicated for the management of pain and inflammation associated with conditions such as osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. It is administered orally in tablet form.

Brand names: Bitugesic AC
Other names: Aceclofenac and Paracetamol Tablet

Targets

PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on aceclofenac + paracetamol (Amvia Biotech).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on aceclofenac + paracetamol (Amvia Biotech).

Explore the full profile